Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyproheptadine + methylphenidate is a non-branded combination of two small molecule drugs, each with distinct mechanisms and indications. Cyproheptadine is an antihistamine with additional antiserotonergic and anticholinergic properties, primarily used to treat allergic symptoms but also used off-label for appetite stimulation and to counteract stimulant-induced weight loss or insomnia in patients treated for attention deficit hyperactivity disorder (ADHD)[4][5][7]. Methylphenidate is a central nervous system stimulant commonly prescribed for ADHD and narcolepsy. The combination is sometimes used in clinical practice—though not as a fixed-dose product—to manage side effects such as appetite suppression or insomnia caused by stimulants like methylphenidate[7]. There are no known direct pharmacological interactions between the two agents, but their combined use should be monitored due to potential additive side effects such as sedation or CNS effects[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyproheptadine + methylphenidate.